Long-term oral contraceptive use does not affect trabecular bone density.
To determine whether long-term exposure to exogenous estrogen in oral contraceptives influences trabecular bone mass in premenopausal women, we studied 25 closely matched, healthy, premenopausal women, who were recruited from an active obstetrics and gynecology practice. Eleven women had never used oral contraceptives, and 14 women had used oral contraceptives for a minimum of 67 months. All oral contraceptive users had used preparations that provided a minimum of 50 micrograms mestranol per day. Trabecular bone density was determined by quantitative single-energy computerized tomography of the L1-3 lumbar vertebral bodies. Trabecular bone density was similar for both the control group and the oral contraceptive users, 160.6 +/- 6.9 versus 161.2 +/- 7.4 mg/ml, respectively. The power to detect a 15% difference in bone density between these two samples was 0.87. We concluded that long-term, premenopausal oral contraceptive use has no effect on vertebral bone density.
Lloyd
T
T
Department of Obstetrics and Gynecology, College of Medicine, Pennsylvania State University, Hershey 17033.
Buchanan
J R
JR
Ursino
G R
GR
Myers
C
C
Woodward
G
G
Halbert
D R
DR
D015502:Absorptiometry, Photon; D000328:Adult; D001842:Bone and Bones / Q000187:drug effects*; D003276:Contraceptives, Oral / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008656:Mestranol / Q000009:adverse effects; D014057:Tomography, X-Ray Computed
D003276:Contraceptives, Oral; D008656:Mestranol